KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study.

Linda Dirven, Abigirl Machingura, Martin J van den Bent, Corneel Coens, Andrew Bottomley, Alba A Brandes, Julien Domont, Ahmed Idbaih, Johan A F Koekkoek, Jaap C Reijneveld, Michael Platten, Wolfgang Wick, Martin J B Taphoorn

Neurooncol Pract 12(2) 209-218

PMID40110057
PMCIDPMC11913650
DOI10.1093/nop/npae091
发表日期2025-03-20
摘要

摘要

BACKGROUND: Progression-free survival, but not overall survival, was prolonged with bevacizumab and lomustine compared to lomustine only in the randomized phase 3 European Organization for Research and Treatment of Cancer (EORTC) 26101 study. OBJECTIVE: To evaluate the impact of treatment on health-related quality of life (HRQoL) in progressive glioblastoma patients participating in the EORTC 26101 study. METHODS: Patients with progressive glioblastoma, after standard radio-chemotherapy, were 2:1 randomized to either BEV/LOM or LOM. HRQoL was a secondary trial outcome and assessed using the EORTC QLQ-C30 and QLQ-BN20 questionnaires at baseline, and subsequently every 12 weeks. Predefined scales for analysis were global health status (GH), physical functioning, social functioning (SF), motor dysfunction, and communication deficit. The primary endpoint was HRQoL during the last assessment up to week 36. Moreover, time to HRQoL deterioration (TTD) and HRQoL deterioration-free survival (DFS) were calculated. RESULTS: Out of 437 patients, 402 (92%) patients had a baseline HRQoL assessment, which dropped to 66% at week 36. During the last assessment up to week 36, no differences were observed for predefined scales, apart from SF being clinically relevant lower in the combination arm (mean 66.0 versus 81.0, p = .001). Of note, the baseline SF score was 66.4 for patients in the combination arm, showing stable SF. Median DFS was significantly longer in the combination arm (12.4 weeks) compared to lomustine alone (6.7 weeks), reflecting the difference in time to progression between arms. TTD, not including progression as an event, was not different between treatment arms (median 13.0 versus 12.9 weeks). CONCLUSION: The addition of bevacizumab to lomustine did not negatively affect HRQoL during the progression-free period.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。